News
List of company announcements and press releases.
Click here for announcements regarding managers transactions.
Click here for news in Danish.
July 01, 2024 | Press Releases
Bavarian Nordic Converts Existing Credit Facility into Sustainability-linked LoanJune 28, 2024 | Press Releases
Bavarian Nordic Joins Global Efforts to Fight Mpox Outbreak in Africa June 26, 2024 | Company Announcements
Bavarian Nordic Submits Marketing Authorization Application for its Chikungunya Vaccine Candidate to EMAJune 17, 2024 | Company Announcements
Bavarian Nordic Completes BLA Submission to U.S. FDA for its Chikungunya Vaccine Candidate May 31, 2024 | Company Announcements
Bavarian Nordic Submits Supplemental BLA Seeking U.S. FDA Approval of Freeze-Dried Formulation of Smallpox and Mpox VaccineMay 30, 2024 | Press Releases
Bavarian Nordic and CEPI Partners to Advance Mpox Vaccination in AfricaMay 22, 2024 | Company Announcements
Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant ExerciseMay 21, 2024 | Company Announcements
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program and Termination of Share Buy-Back ProgramMay 21, 2024 | Company Announcements
EVP and Chief Medical Officer Laurence de Moerlooze Will Be Leaving Bavarian NordicMay 08, 2024 | Company Announcements
Bavarian Nordic Launches Share Buy-Back Program to Hedge Incentive Scheme ObligationsMay 08, 2024 | Company Announcements
Bavarian Nordic Announces Interim Results for the First Three Months of 2024April 29, 2024 | Company Announcements
Bavarian Nordic Receives 65 mEUR Contract to Supply Smallpox Vaccines for EU Strategic ReserveApril 29, 2024 | Company Announcements
Bavarian Nordic Initiates Rolling Submission of Biologics License Application with FDA for its Chikungunya Vaccine Candidate April 16, 2024 | Company Announcements
Resolutions of the Annual General Meeting 2024 of Bavarian Nordic A/SApril 02, 2024 | Press Releases
Bavarian Nordic Announces Commercial Launch of Mpox Vaccine in the U.S.March 21, 2024 | Company Announcements
Bavarian Nordic A/S – Notice Convening Annual General MeetingMarch 13, 2024 | Press Releases
Bavarian Nordic Receives Approval of Smallpox and Mpox Vaccine in SwitzerlandMarch 06, 2024 | Company Announcements
Bavarian Nordic Publishes Annual Report 2023February 23, 2024 | Company Announcements
Bavarian Nordic’s Chikungunya Vaccine Candidate Granted Accelerated Assessment by European Medicines AgencyFebruary 21, 2024 | Company Announcements
Bavarian Nordic delivered record financial results in 2023December 13, 2023 | Company Announcements
New Incentive Program Established for Members of Executive Management and Selected Employees in Bavarian Nordic November 30, 2023 | Company Announcements
Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant ExerciseNovember 16, 2023 | Company Announcements
Bavarian Nordic Announces Interim Results for the First Nine Months of 2023October 25, 2023 | Company Announcements
Bavarian Nordic’s Mpox Vaccine Receives Recommendation from U.S. CDC Advisory Committee for Routine Use in Adults at RiskSeptember 13, 2023 | Press Releases
Bavarian Nordic Awarded Another Contract to Supply Smallpox Vaccines for EU Strategic Reserve